Business Context and Reporting Period
This Form 10-K covers Schering-Plough Corporation for the fiscal year ended December 31, 2007. The company is a global health care firm operating in three segments: Human Prescription Pharmaceuticals, Animal Health, and Consumer Health Care. The reporting period is defined by the transformative acquisition of Organon BioSciences N.V. (OBS) on November 19, 2007, for approximately $16.1 billion. This acquisition added significant strength to the Animal Health segment and expanded the Human Prescription portfolio into Women's Health and Central Nervous System therapeutic areas.
Key Financial Metrics
| Metric | 2007 | 2006 | Change |
|---|---|---|---|
| Net Sales | $12.69 billion | $10.59 billion | +20% |
| Net Loss (Available to Common) | $(1.59) billion | $1.06 billion (Income) | Turned to Loss |
| Operating Cash Flow | $2.63 billion | $2.16 billion | +22% |
| Long-Term Debt | $9.02 billion | $2.41 billion | +274% |
| Equity Income (Merck JV) | $2.05 billion | $1.46 billion | +40% |
| R&D Expenses | $2.93 billion | $2.19 billion | +34% |
Segment Performance (Pre-Tax Profit/Loss):
- Human Prescription Pharmaceuticals: $(1.21) billion loss (2007) vs. $1.39 billion profit (2006). The loss includes $3.4 billion in purchase accounting charges.
- Animal Health: $(0.58) billion loss (2007) vs. $0.12 billion profit (2006). The loss includes $0.72 billion in purchase accounting charges.
- Consumer Health Care: $0.28 billion profit (2007) vs. $0.23 billion profit (2006).
Material Changes vs. Prior Period
The financial results for 2007 were significantly impacted by non-cash charges related to the OBS acquisition. While net sales grew 20% due to the acquisition and organic growth in key products like REMICADE and NASONEX, the company reported a net loss of $1.59 billion compared to a net income of $1.06 billion in 2006.
Primary Drivers of Change:
- Acquisition Charges: Approximately $4.0 billion in charges related to purchase accounting, including a $3.8 billion charge for acquired in-process research and development (IPR&D).
- Debt Financing: Long-term debt increased by $6.6 billion to fund the OBS acquisition, including the issuance of senior unsecured notes and a euro-denominated term loan.
- Equity Income: Equity income from the Merck/Schering-Plough cholesterol joint venture (VYTORIN/ZETIA) increased 40% to $2.05 billion, driven by higher market share and international sales growth.
- Other Income: A one-time net realized gain of $510 million on foreign currency options related to the OBS acquisition contributed to operating cash flow.
Guidance, Outlook, and Risks
Schering-Plough does not provide numeric guidance. However, management highlighted the following outlook and risks:
- ENHANCE Trial Impact: In early 2008, the ENHANCE clinical trial results for the Merck/Schering-Plough cholesterol joint venture (VYTORIN/ZETIA) failed to show a statistically significant difference in the primary endpoint (carotid artery thickness). While the trial confirmed LDL cholesterol lowering, the results triggered media scrutiny, government investigations (Congressional letters and state subpoenas), and a decline in prescriptions in early 2008. Management stated it is too early to determine the long-term financial impact but acknowledged a likely negative impact on first-quarter 2008 joint venture sales.
- Legal Proceedings: The company faces multiple class-action lawsuits regarding the ENHANCE trial disclosures and ongoing investigations into Average Wholesale Price (AWP) practices. A $435 million settlement regarding the Massachusetts Investigation was paid in 2007.
- R&D Outlook: R&D expenses are expected to continue increasing over the next several years due to the expanded pipeline from the OBS acquisition and the need for larger, more frequent clinical trials.
- Regulatory Environment: The company faces increasing scrutiny on pricing, marketing practices, and pharmacovigilance reporting globally.
Investor Verification Checklist
- ENHANCE Trial Fallout: Monitor the trajectory of VYTORIN and ZETIA prescription volumes and the outcome of government investigations and class-action lawsuits related to the trial disclosure timing.
- Acquisition Integration: Verify the realization of anticipated cost synergies from the OBS integration and the progress of the acquired pipeline projects (Women's Health, CNS, Animal Health).
- Debt Servicing: Assess the company's ability to service the significantly increased debt load ($9.02 billion long-term) while maintaining liquidity, given the covenant requirements (net debt to total capital ratio).
- Patent Expirations: Review the status of patent challenges (Paragraph IV certifications) for key products like TEMODAR, ZETIA, and CLARINEX, which could impact future revenue streams.
- Equity Income Volatility: Understand that a significant portion of profitability is derived from the Merck joint venture, which is accounted for via the equity method and is subject to the specific risks of the cholesterol market.